In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months Clesrovimab has the potential to become the...Read more
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease...Read more
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients...Read more
VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV reported superior improvement in "on" time without troublesome dyskinesia, compared to oral...Read more
LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and older through October 16, 2031 DUBLIN, Oct....Read more
US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global Reports Recombinant or inactivated flu vaccines are recommended by the U.S....Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Korro Bio | 40.25 101.23 | $80.01 |
| ZIVO Bioscience | 18.61 1,691.82 | $19.71 |
| Vertex Pharmaceuticals | 14.43 2.98 | $498.73 |
| United Therapeutics | 13.24 3.68 | $372.81 |
| Chemed | 10.62 1.76 | $612.59 |
| Finch Therapeutics | 10.20 566.67 | $12.00 |
| UnitedHealth | 9.74 1.75 | $566.03 |
| Alnylam Pharmaceuticals | 9.39 3.27 | $296.75 |
| Univerl Health Services | 8.82 3.91 | $234.16 |
| Humana | 8.74 3.39 | $266.34 |
| Veeva Systems | 7.02 3.34 | $217.02 |
| Axsome Therapeutics | 6.92 8.01 | $93.35 |
| Wave Life Sciences | 6.05 70.68 | $14.61 |
| Arcellx | 5.36 5.96 | $95.27 |
| HCA Healthcare | 5.22 1.30 | $406.48 |
| 23andMe | 4.64 1,717.85 | $4.91 |
| Cigna | 4.28 1.23 | $353.12 |
| HealthEquity | 4.17 4.97 | $88.00 |
| Company | Volume | Last Trade |
|---|---|---|
| Molecular Templates | 229,845,170 | $0.93 |
| Notable Labs | 143,064,464 | $0.38 |
| Tonix Pharmaceuticals | 90,356,456 | $0.18 |
| Gritstone bio | 44,786,299 | $0.05 |
| Vyome | 36,361,564 | $0.22 |
| Walgreens Boots Alliance | 31,938,151 | $10.66 |
| NKGen Biotech | 19,280,831 | $0.70 |
| Clover Health | 16,963,218 | $4.18 |
| Kazia Therapeutics | 16,743,358 | $0.53 |
| Pfizer | 15,787,984 | $29.27 |
| Centene | 13,221,216 | $63.00 |
| Geron | 12,022,719 | $4.06 |
| Carmell | 10,445,802 | $0.48 |
| Windtree Therapeutics | 10,416,364 | $0.99 |
| Tempest Therapeutics | 10,228,745 | $1.15 |
| Amicus Therapeutics | 10,184,206 | $11.97 |
| Novavax | 9,795,124 | $10.35 |
| Humacyte | 9,568,419 | $4.86 |
| Elevance Health | 8,245,362 | $444.35 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
